Profile: Cell Therapeutics, Inc. provides drugs for cancer treatment. Our pixantrone is a novel DNA major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. It is under development for the treatment of non-Hodgkin's lymphoma (NHL). Opaxio™ is our biologically enhanced chemotherapeutic that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. Taxanes, including paclitaxel & docetaxel are widely used for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. We have brostallicin, a small molecule & chemotherapeutic agent useful in combination with newer, targeted cancer therapies as well as for the treatment of cancer. Brostallicin binds to DNA only in the presence of glutathione (GSH) and glutathione S-transferase (GST), which is produced to a greater extent in cancer cells than in normal cells. By binding to the minor groove, brostallicin provides a new target to interfere with cell division and lead to tumor cell death. Our platinum-based chemotherapy drug cisplatin is used to treat a wide variety of cancer. We develop new analogues of the dinuclear-platinum complex, CT-3610 that is more potent than cisplatin. The novel bisplatinum analogues are rationally designed & synthesized to have improved biopharmaceutical properties that reduce the intrinsic reactivity of the molecule and that demonstrate preclinical anti-tumor efficacy in solid tumor models.